GreenLight Biosciences Long Term Debt

GreenLight Biosciences (GRNA) currently reports a long-term debt of $60M as of March 2023. That compares with $24M in the prior-year period — up 151.5% year over year. Use the charts on this page to explore GreenLight Biosciences's long-term debt history and peer comparisons.

GreenLight Biosciences's long-term debt increased from $24M to $60M — a 151.5% year-over-year increase (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

GreenLight Biosciences reported $60M in long-term debt as of March 2023. That compares with $24M in the prior-year period — up 151.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $60M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for GreenLight Biosciences, and consider following GRNA for alerts when major investors trade the stock.